{"id":"difluprednate-ophthalmic","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Posterior subcapsular cataract"},{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Secondary ocular infection"}]},"_chembl":{"chemblId":"CHEMBL4303220","moleculeType":"Small molecule","molecularWeight":"508.56"},"_dailymed":{"setId":"71121026-1496-4154-b61b-9afe9b62bf2a","title":"DIFLUPREDNATE (DIFLUPREDNATE OPHTHALMIC) EMULSION [ALEMBIC PHARMACEUTICALS LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Difluprednate is a fluorinated prednisolone derivative designed for ophthalmic use with enhanced corneal penetration. It inhibits inflammatory mediators, reduces leukocyte infiltration, and suppresses immune cell activation in ocular tissues. The drug is particularly effective for post-operative inflammation and anterior uveitis due to its superior bioavailability in the anterior segment of the eye.","oneSentence":"Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:25.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-operative inflammation following ocular surgery"},{"name":"Anterior uveitis"},{"name":"Inflammatory conditions of the anterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT06271772","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Bacterial Keratitis","enrollment":60},{"nctId":"NCT06765980","phase":"PHASE1, PHASE2","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Kriya Therapeutics, Inc.","startDate":"2025-05-28","conditions":"Geographic Atrophy Secondary to Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT04631315","phase":"PHASE4","title":"Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2019-03-24","conditions":"Cataract","enrollment":255},{"nctId":"NCT05649111","phase":"PHASE4","title":"A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2022-11-01","conditions":"Uveitis, Anterior","enrollment":20},{"nctId":"NCT04687800","phase":"PHASE4","title":"Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery","status":"TERMINATED","sponsor":"Cathleen McCabe MD","startDate":"2020-12-01","conditions":"Cataract","enrollment":1},{"nctId":"NCT03626376","phase":"PHASE4","title":"Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2019-12-10","conditions":"Herpes Simplex Virus Keratitis","enrollment":""},{"nctId":"NCT01939691","phase":"PHASE4","title":"Macular Edema Nepafenac vs. Difluprednate Uveitis Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-09-12","conditions":"Uveitis, Macular Edema","enrollment":9},{"nctId":"NCT03693989","phase":"PHASE3","title":"Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-10-04","conditions":"Cataract","enrollment":178},{"nctId":"NCT01124045","phase":"PHASE3","title":"Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-08","conditions":"Cataracts, Inflammation","enrollment":80},{"nctId":"NCT01276223","phase":"PHASE2","title":"Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Dry Eye Disease","enrollment":722},{"nctId":"NCT01201798","phase":"PHASE3","title":"Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Endogenous Anterior Uveitis","enrollment":111},{"nctId":"NCT01244334","phase":"PHASE4","title":"Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.","status":"COMPLETED","sponsor":"Edward J. Holland","startDate":"2009-03","conditions":"Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration","enrollment":52},{"nctId":"NCT00616993","phase":"PHASE3","title":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2008-01","conditions":"Inflammation","enrollment":120},{"nctId":"NCT00616070","phase":"PHASE3","title":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2007-12","conditions":"Inflammation","enrollment":120},{"nctId":"NCT00429923","phase":"PHASE3","title":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"","conditions":"Inflammation","enrollment":219},{"nctId":"NCT00430092","phase":"PHASE3","title":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"","conditions":"Inflammation","enrollment":219},{"nctId":"NCT00407225","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"1999-12","conditions":"Inflammation","enrollment":24},{"nctId":"NCT00406341","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2004-04","conditions":"Inflammation","enrollment":200},{"nctId":"NCT00406497","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2003-04","conditions":"Inflammation","enrollment":24},{"nctId":"NCT00407056","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2002-08","conditions":"Uveitis, Panuveitis","enrollment":20},{"nctId":"NCT00406887","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2002-08","conditions":"Anterior Uveitis, Panuveitis","enrollment":140},{"nctId":"NCT00405496","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2000-03","conditions":"Anterior Uveitis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"EYELID PTOSIS"},{"count":1,"reaction":"MOOD ALTERED"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"OCULAR HYPERTENSION"},{"count":1,"reaction":"VISUAL IMPAIRMENT"}],"_approvalHistory":[{"date":"20090320","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20250715","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20160729","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20130515","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20121127","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20251027","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20160411","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20080623","type":"ORIG","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20130322","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20120613","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA022212"},{"date":"20221116","type":"ORIG","sponsor":"DR REDDYS","applicationNumber":"ANDA214894"}],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Difluprednate Ophthalmic","genericName":"Difluprednate Ophthalmic","companyName":"Thomas M. Lietman","companyId":"thomas-m-lietman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Post-operative inflammation following ocular surgery, Anterior uveitis, Inflammatory conditions of the anterior segment of the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}